1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Targeted Protein Degradation Analysis Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Targeted Protein Degradation Analysis Market, by Degradation Platform
8.1.1. Molecular Glue Degraders
8.1.1.1. Market Revenue and Forecast
8.1.2. Lysosome-targeted Degraders
8.1.2.1. Market Revenue and Forecast
8.1.3. PROTACs
8.1.3.1. Market Revenue and Forecast
8.1.4. Autophagy-targeted Degraders
8.1.4.1. Market Revenue and Forecast
8.1.5. Antibody-based targeted Degraders
8.1.5.1. Market Revenue and Forecast
8.1.6. Hydrophobic Tagging–based Degraders
8.1.6.1. Market Revenue and Forecast
8.1.7. Others
8.1.7.1. Market Revenue and Forecast
9.1. Targeted Protein Degradation Analysis Market, by Drug
9.1.1. Thalidomide
9.1.1.1. Market Revenue and Forecast
9.1.2. Lenalidomide
9.1.2.1. Market Revenue and Forecast
9.1.3. Fulvestrant
9.1.3.1. Market Revenue and Forecast
9.1.4. Elacestrant
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Targeted Protein Degradation Analysis Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast
11.1. Targeted Protein Degradation Analysis Market, by Distribution Channel
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Degradation Platform
12.1.2. Market Revenue and Forecast, by Drug
12.1.3. Market Revenue and Forecast, by Route of Administration
12.1.4. Market Revenue and Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Degradation Platform
12.1.5.2. Market Revenue and Forecast, by Drug
12.1.5.3. Market Revenue and Forecast, by Route of Administration
12.1.5.4. Market Revenue and Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Degradation Platform
12.1.6.2. Market Revenue and Forecast, by Drug
12.1.6.3. Market Revenue and Forecast, by Route of Administration
12.1.6.4. Market Revenue and Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Forecast, by Degradation Platform
12.2.2. Market Revenue and Forecast, by Drug
12.2.3. Market Revenue and Forecast, by Route of Administration
12.2.4. Market Revenue and Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Degradation Platform
12.2.5.2. Market Revenue and Forecast, by Drug
12.2.5.3. Market Revenue and Forecast, by Route of Administration
12.2.5.4. Market Revenue and Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Degradation Platform
12.2.6.2. Market Revenue and Forecast, by Drug
12.2.6.3. Market Revenue and Forecast, by Route of Administration
12.2.6.4. Market Revenue and Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Degradation Platform
12.2.7.2. Market Revenue and Forecast, by Drug
12.2.7.3. Market Revenue and Forecast, by Route of Administration
12.2.7.4. Market Revenue and Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Degradation Platform
12.2.8.2. Market Revenue and Forecast, by Drug
12.2.8.3. Market Revenue and Forecast, by Route of Administration
12.2.8.4. Market Revenue and Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Forecast, by Degradation Platform
12.3.2. Market Revenue and Forecast, by Drug
12.3.3. Market Revenue and Forecast, by Route of Administration
12.3.4. Market Revenue and Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Degradation Platform
12.3.5.2. Market Revenue and Forecast, by Drug
12.3.5.3. Market Revenue and Forecast, by Route of Administration
12.3.5.4. Market Revenue and Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Degradation Platform
12.3.6.2. Market Revenue and Forecast, by Drug
12.3.6.3. Market Revenue and Forecast, by Route of Administration
12.3.6.4. Market Revenue and Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Degradation Platform
12.3.7.2. Market Revenue and Forecast, by Drug
12.3.7.3. Market Revenue and Forecast, by Route of Administration
12.3.7.4. Market Revenue and Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Degradation Platform
12.3.8.2. Market Revenue and Forecast, by Drug
12.3.8.3. Market Revenue and Forecast, by Route of Administration
12.3.8.4. Market Revenue and Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Forecast, by Degradation Platform
12.4.2. Market Revenue and Forecast, by Drug
12.4.3. Market Revenue and Forecast, by Route of Administration
12.4.4. Market Revenue and Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Degradation Platform
12.4.5.2. Market Revenue and Forecast, by Drug
12.4.5.3. Market Revenue and Forecast, by Route of Administration
12.4.5.4. Market Revenue and Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Degradation Platform
12.4.6.2. Market Revenue and Forecast, by Drug
12.4.6.3. Market Revenue and Forecast, by Route of Administration
12.4.6.4. Market Revenue and Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Degradation Platform
12.4.7.2. Market Revenue and Forecast, by Drug
12.4.7.3. Market Revenue and Forecast, by Route of Administration
12.4.7.4. Market Revenue and Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Degradation Platform
12.4.8.2. Market Revenue and Forecast, by Drug
12.4.8.3. Market Revenue and Forecast, by Route of Administration
12.4.8.4. Market Revenue and Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Degradation Platform
12.5.2. Market Revenue and Forecast, by Drug
12.5.3. Market Revenue and Forecast, by Route of Administration
12.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Degradation Platform
12.5.5.2. Market Revenue and Forecast, by Drug
12.5.5.3. Market Revenue and Forecast, by Route of Administration
12.5.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Degradation Platform
12.5.6.2. Market Revenue and Forecast, by Drug
12.5.6.3. Market Revenue and Forecast, by Route of Administration
12.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.1. Arvinas, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol Myers Squibb (BMS)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Kymera Therapeutics, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Nurix Therapeutics, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. C4 Therapeutics, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Monte Rosa Therapeutics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Foghorn Therapeutics, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bayer AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Roche Holding AG (Genentech)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
